乙型交感神經阻斷劑眼藥對血漿脂蛋白的影響

Studies on the Relationship between Topical β-Blockers and Serum Lipoprotein

汪正光(Cheng-Kuang Wang) ； 謝瑞玟(Jui-Wen Hsieh)

《中華民國眼科醫學會雜誌》 36卷2期 (1997/06) Pp. 79-83

https://doi.org/10.30048/ACTASOS.199706.0001

摘要

治療高血壓的。服乙型交感神經阻斷劑已被證實對血液中的血漿脂蛋白濃度有不良的影響；而乙型交感神經阻斷劑眼藥又被廣泛地應用在青光眼的治療上，所以我們決定做此研究來探討乙型交感神經阻斷劑眼藥是否會影響血漿脂蛋白的濃度。此篇報告共計收集102位因眼壓升高而使用乙型交感神經阻斷劑眼藥的患者加以統計分析；分析時將樣本分為3組：貝特寧組(Betoptic, 0.5%, n=32)美特朗級(Carteolol, 2%, n-32)及青眼露組(Timolol, 0.25%, n=38)。平均追蹤期三組依序為42.2、40.3及42.3個月，結果顯示乙型交感神經阻斷劑眼藥並不會造成血液中血漿脂蛋白濃度的升高。故我們相信乙型交感神經阻斷劑眼藥在有心職血管相關疾病息者的使用上應是被允許的。

並列摘要

Oral β-blockers taken for the treatment of systemic hypertension had been shown to affect adversely serum lipoprotein levels, so we decided to find the relationship between topical β-blockers and serum lipoprotein in Chinese glaucoma patients.
Ninty-six patients with topical β-blocker therapy for raised intraocular pressure were evaluated. They were devided into three groups for data analysis: Betoptic (n=32), Carteolol (n=32), and Timolol (n=38). The average follow-up duration was 41.6 months.
In this study, the results showed that there was no significant adverse effect on serum lipoprotein levels in all three groups. We believed that selection of topical β-blockers should not be influnced by lipid changes associated with the oral form of the drug.

並列關鍵字

topical β-blocker ； serum Iipoprotein ； Intrinsic Sympathomimetic Activity ISA